Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 496 results for 2011

  1. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (HTG441)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.

  2. Synergo for non-muscle-invasive bladder cancer (HTG601)

    Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.

  3. Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)

    Evidence-based recommendations on erlotinib (Tarceva) for treating EGFR-TK-positive non-small-cell lung cancer in adults.

  4. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (HTG362)

    Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.

  5. Preventing suicide in community and custodial settings (NG105)

    This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:

  6. UroShield for preventing catheter-associated urinary tract infections (HTG620)

    Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.

  7. Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

    Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

  8. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.

  9. Falls (QS86)

    This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:

  10. The NGAL Test for early diagnosis of acute kidney injury (MIB3)

    NICE has developed a medtech innovation briefing (MIB) on the NGAL Test for early diagnosis of acute kidney injury .

  11. Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)

    This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.

  12. Metreleptin for treating lipodystrophy (HST14)

    Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults.

  13. S-Cath System for suprapubic catheterisation (MIB68)

    NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations

  14. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  15. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)

    Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.